BioCentury | Jul 10, 2020
Politics, Policy & Law

Pharmas to invest $1 billion in biotechs to fight AMR as bridge to market reforms

...create reasonable expectations that new antimicrobial products will generate revenues. In a BioCentury Guest Commentary, Lars...
BioCentury | May 13, 2020
Product Development

Phase III obesity data show Novo’s semaglutide nearing threshold to replace gastric bypass surgery

...and 3 -- were completed between April 19 and May 1. Novo President and CEO Lars...
BioCentury | Mar 11, 2020
Product Development

Novo’s year of obesity

...the setting on which Novo has built its business. However, Novo Nordisk President and CEO Lars...
...needs to be developed, and we need to do that on a number of dimensions.” Lars...
...mechanisms, we believe we can get into the area of bariatric surgery in an injection.” Lars...
BioCentury | Feb 29, 2020
Management Tracks

Brandicourt joins Alnylam's board: plus Bayer, Jazz, Halozyme, Arena, Aurinia, Adverum, Neoleukin, Centogene, Epirium, Insilico, Nouscom, Eloxx, Nordic, Summit,

...Nordic Nanovector ASA (OSE:NANO) said CEO Eduardo Bravo stepped down to pursue other opportunities. CTO Lars...
BioCentury | Feb 1, 2020
Preclinical News

Cellular fluorescence assay to assess allosteric modulator potency in drug discovery

...spectroscopy (FCCS) to evaluate the potency of allosteric modulators and predict therapeutic activity. Study author Lars...
BioCentury | Jan 22, 2020
Finance

HepaRegeniX aims to bring liver program into clinic with €11M insider round

...is a work in progress.” Michael Lutz, HepaRegeniX HepaRegeniX is based on work by co-founder Lars...
BioCentury | Jan 17, 2020
Finance

The AMR crisis is solvable -- but we must act together and fast

...for a bleak future, returning to a pre-antibiotic era -- undermining many modern medicinal advances.” Lars...
...both short and long-term solutions. “We need to expand and build on existing ‘push’ initiatives.” Lars...
...resistance crisis. Lars Rebien Sørensen is chairman of The Novo Nordisk Foundation and Novo Holdings A/S. Lars...
BioCentury | Aug 20, 2019
Company News

Management tracks: uniQure, Provention, Anaptys, FDA and more

...Christian Holzherr on the supervisory board. Blood cancer company Nordic Nanovector ASA (OSE: NANO) hired Lars...
BioCentury | Apr 12, 2019
Company News

Gilead, Novo team up to combine NASH compounds

...as Ozempic for Type II diabetes, in Phase II testing for NASH. President and CEO Lars...
BioCentury | Mar 8, 2019
Targets & Mechanisms

Oral insulin innovation

...in nature. The result is still in the 1% bioavailability range.” Mir Imran, Rani Therapeutics Lars...
...“The key obstacle for oral insulin is to work the very, very narrow therapeutic window.” Lars...
Items per page:
1 - 10 of 365